Skip to main content
. 2022 Jul 6;10(7):e005025. doi: 10.1136/jitc-2022-005025

Figure 5.

Figure 5

Stromal CD11b levels were significantly higher in KRAS-mutant tumors than in EGFR-mutant tumors. In Cohort 3, the only cohort with annotated KRAS/EGFR mutation status, stromal CD11b levels were higher in KRAS-mutant tumors than in EGFR-mutant tumors (p=0.006). CK, cytokeratin; DAPI, 4’,6-Diamidino-2-Phenylindole; QIF, quantitative immunofluorescence; WT, wild type.